Ribeiro J M, Costas M J, Cameselle J C
Unidad de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Extremadura, Badajoz, Spain.
J Biochem Mol Toxicol. 1999;13(3-4):171-7. doi: 10.1002/(sici)1099-0461(1999)13:3/4<171::aid-jbt7>3.0.co;2-v.
Free ADP-ribose reacts nonenzymatically with proteins and can lead to intracellular damage. The low-Km ADP-ribose pyrophosphatase-I (ADPRibase-I) is well suited to control free ADP-ribose and nonenzymatic ADP-ribosylation. In vitro, the acetaminophen metabolite N-acetyl-p-benzoquinoneimine (NAPQI) decreases ADPRibase-I Vmax and increases Km, effects not reverted by dithiothreitol (DTT) and attributed to enzyme arylation. The present study was conducted to test whether acetaminophen overdose affected ADPRibase-I in vivo. Rats pretreated with 3-methylcholanthrene and L-buthionine-[S,R]-sulfoximine to potentiate acetaminophen toxicity received an intraperitoneal dose of either acetaminophen (800 mg/ kg; n = 5) or vehicle (n = 3). ADPRibase-I partially purified from acetaminophen-overdosed rats showed a decreased Vmax (0.32+/-0.09 versus 0.60+/-0.03 mU/mg of liver protein; p<0.01) not reverted by DTT and an increased Km for ADP-ribose (1.39+/-0.31 versus 0.67+/-0.05 microM; p<0.01) that, contrary to the in vitro NAPQI effect, was reverted by DTT. Incubation of partially purified ADPRibase-I from normal rat liver with oxidized glutathione elicited a time- and dose-dependent, DTT-reverted increase of Km, without change of Vmax. The results indicate that the activity of ADPRibase-I can be regulated by thiol exchange and that the increase of Km, elicited by acetaminophen overdosage was related to the oxidative stress caused by the drug. It remains to be seen whether an increase of free ADP-ribose concomitant to ADPRibase-I inhibition could contribute to the hepatotoxicity of acetaminophen.
游离的ADP-核糖可与蛋白质发生非酶反应,并可能导致细胞内损伤。低Km的ADP-核糖焦磷酸酶-I(ADPRibase-I)非常适合控制游离的ADP-核糖和非酶ADP-核糖基化。在体外,对乙酰氨基酚代谢产物N-乙酰-p-苯醌亚胺(NAPQI)可降低ADPRibase-I的Vmax并增加Km,二硫苏糖醇(DTT)不能逆转这些效应,这归因于酶的芳基化。本研究旨在测试对乙酰氨基酚过量服用在体内是否会影响ADPRibase-I。用3-甲基胆蒽和L-丁硫氨酸-[S,R]-亚砜亚胺预处理以增强对乙酰氨基酚毒性的大鼠接受腹腔注射对乙酰氨基酚(800 mg/kg;n = 5)或赋形剂(n = 3)。从对乙酰氨基酚过量的大鼠中部分纯化的ADPRibase-I显示Vmax降低(0.32±0.09对0.60±0.03 mU/mg肝蛋白;p<0.01),DTT不能逆转,并且ADP-核糖的Km增加(1.39±0.31对0.67±0.05 μM;p<0.01),与体外NAPQI的效应相反,DTT可逆转该增加。用氧化型谷胱甘肽孵育正常大鼠肝脏中部分纯化的ADPRibase-I会引起Km的时间和剂量依赖性增加,且DTT可逆转,而Vmax不变。结果表明,ADPRibase-I的活性可通过硫醇交换进行调节,对乙酰氨基酚过量引起的Km增加与该药物引起的氧化应激有关。ADPRibase-I抑制伴随的游离ADP-核糖增加是否会导致对乙酰氨基酚的肝毒性还有待观察。